Key result
Medical treatment of triple-vessel coronary artery disease in Japanese patients resulted in 5- and 10-year survival rates of 80.7% and 64.2%, respectively.
Observational (n=198)
No
Medical therapy for triple-vessel coronary artery disease yields poor long-term survival, particularly in patients with reduced ejection fraction or multiple chronic total occlusions, suggesting a need for revascularization.
Answers are grounded in this paper and cite their sources.
Limited long-term survival with medical therapy for triple-vessel CAD should not yet change practice; leaves open revascularization benefit in similar cohorts.
The long-term outcome in 198 patients with triple-vessel disease (TVD) treated medically was investigated. The patients, who underwent coronary angiography between September 1973 and February 1984, had significant (75% or more) stenotic lesions in all three major coronary arteries. The mean follow-up period was 8.4 years. The 5- and 10-year survival rates were 80.7% and 64.2%, respectively. Cardiac death occurred in 73 patients (36.9%) and nonfatal cardiac events developed in 60 patients (30.9%) during follow-up. When cardiac death and nonfatal myocardial infarction (MI) were defined as cardiac events, the annual attrition rate was 4.7%. There was no difference in survival with regard to the presence or absence of MI, the site of infarction, or the presence of total occlusion. In the AP group, however, the survival rate decreased as the number of totally-occluded arteries increased. In the MI group, the survival rate was not altered by the number of totally-occluded arteries, but was affected by the ejection fraction (EF). The 5-year survival rate was better in patients with good left ventricular function (EF > or = 60%) than in those with impaired left ventricular function (EF < 60%), although the 10-year survival rate was similarly low in both groups. Revascularization such as PTCA or CABG might improve the long-term outcome in patients with TVD.
No takes yet. Share an insight, caveat, or question.
Nishiyama et al. (1998) conducted an observational in Triple-vessel coronary artery disease (n=198). Medical treatment was evaluated on 10-year survival rate. Medical treatment of triple-vessel coronary artery disease in Japanese patients resulted in 5- and 10-year survival rates of 80.7% and 64.2%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: